Relay Therapeutics (RLAY) Assets (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Assets of $699.6 million for Q1 2026, down 12.48% year-over-year from $799.4 million in Q1 2025, and up 12.6% quarter-over-quarter from $621.3 million in Q4 2025.
Relay Therapeutics (RLAY) Assets (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Assets for 8 consecutive years, with $699.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets fell 12.48% year-over-year to $699.6 million; the TTM figure through Mar 2026 stood at $699.6 million (down 12.48% YoY), while the FY2025 annual figure was $621.3 million, down 28.69% from the prior year.
- Assets advanced to $699.6 million in Q1 2026 per RLAY's latest filing, from $621.3 million in the prior quarter.
- Across five years, Assets topped out at $1.2 billion in Q3 2022 and bottomed at $621.3 million in Q4 2025.
- Historically, Assets has averaged $870.2 million across 5 years, with a median of $871.3 million in 2024.
- Annual changes were most pronounced in 2022 — Assets jumped 176443.5% — and 2025, when it slipped 28.69%.
- Relay Therapeutics' Assets stood at $1.1 billion in 2022, then slipped by 23.26% to $844.0 million in 2023, then grew by 3.24% to $871.3 million in 2024, then retreated by 28.69% to $621.3 million in 2025, then grew by 12.6% to $699.6 million in 2026.
- Business Quant data shows RLAY's Assets at $699.6 million in Q1 2026, $621.3 million in Q4 2025, and $670.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | 967.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 967.46 Mn |
| Mar 31, 2026 | 699.61 Mn |
| Dec 31, 2025 | 621.33 Mn |
| Sep 30, 2025 | 670.00 Mn |
| Jun 30, 2025 | 728.84 Mn |
| Mar 31, 2025 | 799.36 Mn |
| Dec 31, 2024 | 871.30 Mn |
| Sep 30, 2024 | 930.12 Mn |
| Jun 30, 2024 | 772.55 Mn |
| Mar 31, 2024 | 841.44 Mn |
| Dec 31, 2023 | 843.98 Mn |
| Sep 30, 2023 | 906.96 Mn |
| Jun 30, 2023 | 962.02 Mn |
| Mar 31, 2023 | 1.04 Bn |
| Dec 31, 2022 | 1.10 Bn |
| Sep 30, 2022 | 1.17 Bn |
| Jun 30, 2022 | 889.42 Mn |
| Mar 31, 2022 | 949.88 Mn |
| Dec 31, 2021 | 1.01 Bn |
| Sep 30, 2021 | 662,000.00 |